Liver disorders in diabetic patients;Onemocnění jater u diabetiků

Vnitrni Lekarstvi

Volumn 59, Issue 7, 2013, Pages 546-550

  Bruha R ^a   Dvorak K ^a   Petrtyl J ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Cirrhosis; Liver steatosis; NAFLD; NASH; Type 2 diabetes mellitus

Indexed keywords

ACUTE LIVER FAILURE; ARTICLE; DIABETES MELLITUS; DIABETIC PATIENT; DISEASE ASSOCIATION; DYSLIPIDEMIA; FATTY LIVER; HIGH RISK PATIENT; HUMAN; HYPERTENSION; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER DISEASE; LIVER FIBROSIS; NONALCOHOLIC FATTY LIVER; OBESITY; WEIGHT REDUCTION; CHRONIC HEPATITIS C; COMPLICATION; INSULIN RESISTANCE; LIVER TUMOR; METABOLIC SYNDROME X; METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; RISK REDUCTION;

CARCINOMA, HEPATOCELLULAR; DIABETES MELLITUS, TYPE 2; HEPATITIS C, CHRONIC; HUMANS; INSULIN RESISTANCE; LIVER CIRRHOSIS; LIVER DISEASES; LIVER NEOPLASMS; METABOLIC SYNDROME X; NON-ALCOHOLIC FATTY LIVER DISEASE; RISK REDUCTION BEHAVIOR; WEIGHT LOSS;

EID: 84882250109     PISSN: 0042773X     EISSN: 18017592     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Seppälä-Lindroos A, Vehkavaara S, Hakkinen AM et al. Fat accumulation in the liver is associated with defects in insulin suppression of glucose production and serum free fatty acids independent of obesity in normal men. J Clin Endocrinol Metab 2002;87:3023-3028. (Pubitemid 34816338)
2. Rashid S, Watanabe T, Sakaue T et al. Mechanism of HDL lowering in insulin resistant, hypertriglyceridemic states: the combined effect of HDL triglyceride enrichment and elevated hepatic lipase activity. Clin Biochem 2003;36:421-429. (Pubitemid 37083556)
3. Czaja MJ. JNK regulation of hepatic manifestations of the metabolic syndrome. Trends Endocrinol Metab 2010;21:707-713.
4. El-Serag HB, Tran T, Everhart JE. Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology 2004;126:460-468. (Pubitemid 38182303)
5. de Marco R, Locatelli F, Zoppini G et al. Cause-specific mortality in type 2 diabetes. The Verona Diabetes Study. Diabetes Care 1999;22:756-761. (Pubitemid 29220775)
6. Brodanová M. Diabetes mellitus a játra. Vnitř Lék 2001;47:238-244.
7. Brùha R. Nealkoholová steatóza a steatohepatitída-editorial. Vnitø Lék 2010;56:173-175.
8. Marchesini G, Bugianesi E, Forlani G et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 2003;37:917-923. (Pubitemid 36397405)
9. Chitturi S, Abeygunasekera S, Farrell GC et al. NASH and insulin resistance: Insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology 2002;35:373-379. (Pubitemid 34106377)
10. Ludwig J, Viggiano RT, McGill DB et al. Nonalcoholic steatohepatitis: Mayo Clinic experience with a hitherto unnamed disease. Mayo Clin Proc 1980;55:434-438. (Pubitemid 10057164)
11. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002;346:1221-1231.
12. Ehrmann J, Hùlek P et al. Hepatologie. Praha: Grada Publishing 2010.
13. Wieckowska A, McCullough AJ, Feldstein AE. Noninvasive diagnosis and monitoring of nonalcoholic steatohepatitis: present and future. Hepatology 2007;46:582-589. (Pubitemid 47344794)
14. Sandrin L, Fourquet B, Hasquenoph JM et al. Transient elastography: a new noninvasive method for assessment of hepatic fibrosis. Ultrasound Med Biol 2003;29:1705-1713. (Pubitemid 38091720)
15. Rifai K, Cornberg J, Mederacke I et al. Clinical feasibility of liver elastography by acoustic radiation force impulse imaging (ARFI). Dig Liver Dis 2011;43:491-497.
16. Adams LA, Lymp JF, St Sauver J et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 2005;129:113-121. (Pubitemid 41002048)
17. Caldwell S, Argo C. The natural history of non-alcoholic fatty liver disease. Dig Dis 2010;28:162-168.
18. Matteoni CA, Younossi ZM, Gramlich T et al. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999;116:1413-1419. (Pubitemid 29258890)
19. Hultcrantz R, Glaumann H, Lindberg G et al. Liver investigation in 149 asymptomatic patients with moderately elevated activities of serum aminotransferases. Scand J Gastroenterol 1986;21:109-113. (Pubitemid 16177472)
20. Cortez-Pinto H, Baptista A, Camilo E et al. Nonalcoholic steatohepatitis clinicopathological comparison with alcoholic hepatitis in ambulatory and hospitalized patients. Dig Dis Sci 1996;41:172-179. (Pubitemid 26064854)
21. Bellentani S, Saccoccio G, Costa G et al. Drinking habits as cofactors of risk for alcohol induced liver damage. The Dionysos Study Group. Gut 1997;41:845-850.
22. Snow WM, Murray R, Ekuma O et al. Alcohol use and cardiovascular health outcomes: a comparison across age and gender in the Winnipeg Health and Drinking Survey Cohort. Age Ageing 2009;38:206-212.
23. Bellentani S, Dalle Grave R, Suppini A et al. Behavior therapy for nonalcoholic fatty liver disease: the need for a multidisciplinary approach. Hepatology 2008;47:746-754. (Pubitemid 351280743)
24. Ueno T, Sugawara H, Sujaku K et al. Therapeutic effects of restricted diet and exercise in obese patients with fatty liver. J Hepatol 1997;27:103-107. (Pubitemid 27357062)
25. Musso G, Bambino R, Cassader M et al. A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease. Hepatology 2010;52:79-104.
26. Mahady SE, Webster AC, Walker S et al. The role of thiazolidinediones in non-alcoholic steatohepatitis - a systematic review and meta analysis. J Hepatol 2011;55:1383-1390.
27. Sanyal AJ, Chalasani N, Kowdley KV et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med 2010;362:1675-1685.
28. Li W, Zheng L, Sheng C et al. Systematic review on the treatment of pentoxifylline in patients with non-alcoholic fatty liver disease. Lipids Health Dis 2011;10:49.
29. Hickman IJ, Macdonald GA. Impact of diabetes on the severity of liver disease. Am J Med 2007;120:829-834. (Pubitemid 47451297)
30. Tolman KG, Fonseca V, Dalpiaz A et al. Spectrum of liver disease in type 2 diabetes and management of patients with diabetes and liver disease. Diabetes Care 2007;30:734-743. (Pubitemid 46354365)
31. Caldwell SH, Oelsner DH, lezzoni JC et al. Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease. Hepatology 1999;29:664-669. (Pubitemid 29109578)
32. Wideroff L, Gridley G, Mellemkjaer L et al. Cancer incidence in a population-based cohort of patients hospitalized with diabetes mellitus in Denmark. J Natl Cancer Inst 1997;89:1360-1365. (Pubitemid 27418027)
33. Nair S, Mason A, Eason J et al. Is obesity an independent risk factor for hepatocellular carcinoma in cirrhosis? Hepatology 2002;36:150-155. (Pubitemid 34700772)
34. El-Serag HB, Everhart JE. Diabetes increases the risk of acute hepatic failure. Gastroenterology 2002;122:1822-1828. (Pubitemid 34651427)
35. Chan KA, Truman A, Gurwitz JH et al. A cohort study of the incidence of serious acute liver injury in diabetic patients treated with hypoglyccmic agents. Arch Intern Med 2003;163:728-734. (Pubitemid 36343367)
36. White DL, Ratziu V, El-Serag HB. Hepatitis C infection and risk of diabetes: a systematic review and meta-analysis. J Hepatol 2008;49:831-844.
37. Miyamoto H, Moriishi K, Moriya K et al. Involvement of the PA28gamma-dependent pathway in insulin resistance induced by hepatitis C virus core protein. J Virol 2007;81:1727-1735. (Pubitemid 46214447)
38. Romero-Comez M, Del Mar. Viloria M, Andrade RJ et al. Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. Gastroenterology 2005;128:636-641. (Pubitemid 40585366)
39. Fabris P, Floreani A, Tositti G et al. Type 1 diabetes mellitus in patients with chronic hepatitis C before and after interferon therapy. Aliment Pharmacol Ther 2003;18:549-558. (Pubitemid 37186604)